The company expects the transaction, which was announced in February, to close in the third quarter of 2025.
FibroGen, Inc. (FGEN) on Monday said that a Chinese regulator has approved the sale of its unit FibroGen International (Hong Kong) to AstraZeneca (AZN).
Add Asianet Newsable as a Preferred Source
FibroGen had announced the sale of its China unit to AstraZeneca for about $160 million in February. The closing of the transaction is now expected in the third quarter of 2025, the company said.
Get updates to this developing story <directly on Stocktwits.<
